Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 330 participants.
Also called NCT06274801
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 330 participants
- Sponsor
- Gossamer Bio USA, Inc.
- Registry
-
NCT06274801 -
2023-506334-75
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, Colombia, Czechia, Denmark, France, Germany, Greece, Ireland, Israel, Italy, Japan, Latvia, Lithuania, Mexico, Netherlands, Poland, Portugal, Romania, Saudi Arabia, Serbia, Singapore, South Korea, Spain, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT06274801. Allocation not applicable; no masking; primary purpose treatment. Start 2024-09-03 (actual); primary completion 2026-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
- Condition
- Pulmonary Arterial Hypertension
- Intervention (Drug)
- Seralutinib
- Intervention (Device)
- Gereic Dry Powder Inhaler
- Lead sponsor
- Gossamer Bio USA, Inc.
Record details
- Record id
cardio:ct-nct06274801- Content hash
729f9508db702b3b4f81c7b00afd9ef63b8f294a24bfbb641c24a62cebd28743